Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 306-07-0 Chemical Structure| 306-07-0

Structure of Pargyline HCl
CAS No.: 306-07-0

Chemical Structure| 306-07-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pargyline HCl is an irreversible and selective MAO-B inhibitor with Ki values of 15 and 1.8 μM for MAO-A and MAO-B, respectively.

Synonyms: Pargyline (hydrochloride); Pargyline hydrochloride; Pargyline

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pargyline HCl

CAS No. :306-07-0
Formula : C11H14ClN
M.W : 195.69
SMILES Code : C#CCN(CC1=CC=CC=C1)C.[H]Cl
Synonyms :
Pargyline (hydrochloride); Pargyline hydrochloride; Pargyline
MDL No. :MFCD00012492
InChI Key :BCXCABRDBBWWGY-UHFFFAOYSA-N
Pubchem ID :9373

Safety of Pargyline HCl

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P301+P310
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Target
  • MAO-B

    MAO-B, Ki:0.5 μM

  • MAO-A

    MAO-A, Ki:13 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Adult mouse cardiomyocytes 100 µM 2 hours To assess the effect of MAO inhibition on ROS formation induced by high glucose (HG) and pro-inflammatory cytokine IL-1β. Results showed that pargyline treatment reduced ROS formation. PMC6015497
Mouse granulosa cells 1 μM 2 hours To study the effect of MAO and SERT activity on 5-HT accumulation, results showed pargyline significantly increased 5-HT accumulation, while fluoxetine prevented this effect PMC9739058
Mouse granulosa cells 10 μM 2 hours To study the effect of MAO activity on 5-HT accumulation, results showed pargyline significantly increased 5-HT accumulation in granulosa cells PMC9739058
Human iPSC-beta cells 5 μM 24 hours To evaluate the protective effect of Pargyline against ER stress-induced apoptosis, results showed Pargyline decreased cell apoptosis. PMC7502486
Human stem cell-derived βcells 5 μM 24 hours To evaluate the effect of Pargyline on human βcell metabolism, it was found that Pargyline partially increased glycolysis but did not improve glucose-stimulated insulin secretion. PMC11981795
NIT-1 mouse βcell line 5-100 μM 24-48 hours To investigate the effect of Pargyline on βcell metabolism, results showed that Pargyline partially mimicked the metabolic protection of genetic Rnls inhibition but not completely. PMC11981795
Neonatal rat ventricular myocytes (NRVMs) 100 µM 48 hours To assess the effect of MAO inhibition on ROS formation induced by high glucose (HG) and pro-inflammatory cytokine IL-1β. Results showed that pargyline treatment normalized ROS levels. PMC6015497
NOD.scid islet cells 2 μg/mL 5 hours To evaluate the protective effect of Pargyline against ER stress-induced apoptosis, results showed Pargyline decreased caspase-3 activation. PMC7502486

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD mice Diabetic NOD Mice model Oral 5 μg/ml Continuous administration To evaluate the protective effect of Pargyline on transplanted beta cells, results showed Pargyline treatment allowed transplanted beta cells to survive in diabetic mice, produce insulin and reverse hyperglycemia. PMC7502486
Mice Wild-type Mice hippocampal slices Hippocampal slice perfusion 1 µM Single treatment, lasting 20 minutes To investigate the effect of Pargyline (MAO-B inhibitor) on LTP impairment induced by mitovesicles from Ts2 mice. Results showed that pretreatment with Pargyline eliminated the ability of Ts2 mitovesicles to impair LTP. PMC11017499
Mice MPTP-induced acute, subchronic, and chronic models of Parkinson’s disease Intraperitoneal injection 10 mg/kg Single administration To test the protective effect of compounds on MPTP-induced striatal dopamine depletion and motor dysfunction, results showed significant protection of striatal dopamine content and restoration of motor function in animals PMC4711075
C57BL/KalwRij mice 5TGM1 model Intraperitoneal injection 100 mg/kg 5 times per week for 30 days To evaluate the effect of combination therapy of pargyline with bortezomib on tumor burden, a significant reduction in tumor burden was observed. PMC8805317
Mice Akita diabetes model Oral 25-50 mg/mL Daily for 4 weeks To evaluate the effect of Pargyline on glycemia and βcell function in Akita mice, results showed that Pargyline improved glycemia and partially preserved βcell function. PMC11981795
C57BL6/J mice Type 1 diabetes model Intraperitoneal injection 50 mg/kg Once daily for 12 weeks To evaluate the protective effect of MAO inhibitor Pargyline on diabetic hearts. Results showed that Pargyline treatment significantly restored AKT activation in diabetic hearts and improved cardiac function. PMC9454570
C57BL6/J mice Streptozotocin (STZ)-induced type 1 diabetes model Intraperitoneal injection 50 mg/kg Once daily for 12 weeks To assess the effect of MAO inhibition on cardiac function in diabetic mice. Results showed that pargyline treatment improved diastolic function, reduced cardiac fibrosis, and prevented mast cell degranulation. PMC6015497
Zebrafish (Danio rerio) TPH2 deficiency model Aquarium water administration 0.5 mg/L 72 hours continuous To evaluate the effects of Pargyline on behavior, 5-HT and BDNF systems in zebrafish with TPH2 deficiency. Results showed that Pargyline increased brain 5-HT levels, decreased 5-HIAA levels, and affected the expression of BDNF-related genes. PMC8657639
Zebrafish Zebrafish novel tank test Water exposure 10, 30, and 100 mg/L Single administration, 20 minutes duration Evaluate the effect of Pargyline on anxiety-like behavior in zebrafish. Results showed that Pargyline exhibited an anxiogenic-like effect only at the lowest tested concentration (10 mg/L) during the first 1 min of the test, with no significant effects at other concentrations or time points. PMC8165606

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.11mL

1.02mL

0.51mL

25.55mL

5.11mL

2.56mL

51.10mL

10.22mL

5.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories